Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · IEX Real-Time Price · USD
5.42
+0.04 (0.74%)
At close: May 31, 2024, 4:00 PM
5.52
+0.10 (1.85%)
After-hours: May 31, 2024, 6:53 PM EDT
Company Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| IPO Date | Jan 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Peter S. Greenleaf M.B.A. |
Contact Details
Address: #140, 14315 - 118 Avenue Edmonton, A0 T5L 4S6 Alberta, Canada | |
| Phone | 250-744-2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 98-1231763 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter S. Greenleaf M.B.A. | President, Chief Executive Officer and Director |
| Joseph M. Miller CPA | Chief Financial Officer |
| Matthew Maxwell Donley M.B.A. | Executive Vice President of Operations and Strategy |
| Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Volker Knappertz D.Sc., M.D. | Executive Vice President of Research and Development |
| Andrea Levin Christopher | Head of the Corporate Communications and Investor Relations |
| Fran Lynch | Vice President of Sales |
| Michael R. Martin | Chief Business Officer |
| Sue Evans | Senior Vice President of Global Regulatory Affairs |
| Scott Habig | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 3, 2024 | ARS | Filing |
| May 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 3, 2024 | DEF 14A | Other definitive proxy statements |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |
| Mar 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 10-K | Annual Report |
| Feb 15, 2024 | 8-K | Current Report |